Jaekyung Cheon

8PUBLICATIONS
77CO-AUTHORS
Cancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)Korean languagePredictive and prognostic markersEpidemiological modelling
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Nov 13, 2025
Bevacizumab plus Erlotinib in Advanced Solid Cancers with Krebs Cycle Gene Mutations: A Multicenter Phase II Study (BRISK; KCSG AL22-16).

Hyehyun Jeong, Changhoon Yoo, Shinkyo Yoon

|Oct 27, 2023
Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study.

Vincent Joerg, Bernhard Scheiner, Antonio D Alessio

|Mar 07, 2023
Experience and perspectives of end-of-life care discussion and physician orders for life-sustaining treatment of Korea (POLST-K): a cross-sectional study.

Hyeon-Su Im, Insook Lee, Shinmi Kim

|Dec 11, 2022
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.

Yue Linda Wu, Claudia Angela Maria Fulgenzi, Antonio D'Alessio

|Jul 21, 2022
The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma.

Han Sang Kim, Chang Gon Kim, Jung Yong Hong

|Apr 12, 2022
Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study.

Beom Kyung Kim, Jaekyung Cheon, Hyeyeong Kim

Pageof 2

Frequent Collaborators

4 joint publications

Hong Jae Chon

2 joint publications

Johann von Felden

2 joint publications

Yi-Hsiang Huang

2 joint publications

Hyeon-Su Im